Galectin Therapeutics doses first patient in second cohort under Phase 1 trial of GR-MD-02
M2 - Fri Apr 18, 7:15AM CDT
Therapeutics company Galectin Therapeutics (NasdaqCM:GALT) said on Thursday that it has dosed its first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Galectin Therapeutics Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 3:15PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galectin Thersapeutics , a clinical-stage...
Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis
GlobeNewswire - Thu Apr 17, 9:19AM CDT
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis has been successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. Cohort 2, as with all phases of the clinical trial, was initiated in full compliance with the rules, regulations, and specific conditions set forth by the U.S. Food and Drug Administration (FDA) for this Phase 1 clinical trial. The second cohort follows highly successful results from the first cohort showing that 2 mg/kg was safe and very well tolerated, and that GR-MD-02 treatment resulted in significant improvement in multiple biomarkers of fibrosis and liver inflammation in patients with NASH with advanced fibrosis (see full results: http://galectintherapeutics.com/wp-content/up...FINAL.pdf). The remaining patients in cohort 2 are expected to be enrolled over the next few weeks and we anticipate reporting the results of cohort 2 around the end of July.
Recent Acquisitions, Trial Opinions, Upcoming Earnings, Inducement Grants, and Clinical Trial Results - Analyst Notes on Actavis, The Medicines Company, Hospira, Horizon Pharma, and Galectin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), The Medicines Company (NASDAQ: MDCO), Hospira, Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP), and Galectin Therapeutics Inc. (NASDAQ: GALT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
Galectin Therapeutics (GALT) Falls: Stock Goes Down 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:38AM CDT
Galectin has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
First Cohort Results in Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis
GlobeNewswire - Mon Mar 31, 3:37PM CDT
-- GR-MD-02 was safe and well tolerated in patients
96.5% Return Seen to Date on SmarTrend Galectin Therapeutic Call (GALT)
Comtex SmarTrend(R) - Fri Mar 28, 4:43PM CDT
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 4 months, Galectin Therapeutic has returned 96.50% as of today's recent price of $15.72.
Leading Companies Being Defined in the Hunt for a NASH Treatment
ACCESSWIRE - Thu Mar 27, 9:32AM CDT
March 27, 2014 / The race to develop a treatment for Non-Alcoholic Steatohepatitis (NASH) is getting a lot of airtime lately, pointing to the severity of the disease, poor prognosis and desperate need for a treatment. The space has only a handful of competitors, with most seeing rising valuations due to the tremendous peak sales that analysts are projecting for products that make it to market. What is particularly unique to this disease is not only the lack of any approved treatments, but also the influx of attention and growing broad body of research by companies like Intercept Pharmaceuticals (NASDAQ: ICPT), Galmed Pharmaceuticals (NASDAQ: GLMD) and Galectin Therapeutics (NASDAQ: GALT) that shows treatments are on the horizon, which gives these equities considerable upside.
Galectin Therapeutics, Inc. (GALT) in Focus: Stock Moves Up 8.84% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:44AM CDT
Galectin Therapeutics, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Why Plug Power, Varonis Systems, and Galectin Therapeutics Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 4:15PM CDT
It was another day of mixed data for the broad-based S&P 500 , but this time investors were able to look past recent housing weakness and latch on to improved consumer outlooks. The big driver today was the Conference Board's final...
Galectin: Mark The Date. Drug Data Are Coming And We're Selling Stock.
at The Street - Tue Mar 25, 12:29PM CDT
How to promote your stock, Galectin style.
Why Galectin Therapeutics, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 12:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galectin Therapeutics , a clinical-stage...